Trial of Roflumilast in Asthma Management (TRIM)

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 3, 2018

Primary Completion Date

July 30, 2021

Study Completion Date

July 30, 2021

Conditions
AsthmaObesity
Interventions
DRUG

Roflumilast 500 Mcg Oral Tablet

The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.

DRUG

Placebo oral capsule

The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.

Trial Locations (7)

10029

Mount Sinai Icahn School of Medicine, New York

27705

Duke University, Durham

35294

University of Alabama Lung Health Center, Birmingham

60608

University of Illinois at Chicago, Breathe Chicago Center, Chicago

60611

Northwestern University Feinberg School of Medicine, Chicago

85724

University of Arizona, Tucson

05446

University of Vermont, Colchester

All Listed Sponsors
collaborator

American Lung Association

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Johns Hopkins University

OTHER

NCT03532490 - Trial of Roflumilast in Asthma Management (TRIM) | Biotech Hunter | Biotech Hunter